Quotient Clinical has completed its first clinical program in Japanese healthy volunteers using its Translational Pharmaceutics platform. Bridging studies conducted outside of Japan ensure that drugs that are to be marketed in Japan have been thoroughly evaluated in the Japanese population.
 
This program was a first-in-human investigation, performed on behalf of a U.S. sponsor, and is a four part clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a new drug candidate targeting an undisclosed orphan disease.  
 
The Translational Pharmaceutics platform integrates formulation development, real-time GMP manufacturing and clinical testing, allowing the drug product to be adapted based on emerging clinical data. The inclusion of first generation Japanese volunteers into one part of the study accelerated the transition into downstream clinical trials in Japan.
 
Ian Nisbet, vice president of Clinical Operations, said, “We are delighted to extend our core Translational Pharmaceutics services to now include Japanese volunteers. Recruitment was undertaken in partnership with UK Chiken Services Ltd, an experienced company, which specializes in Japanese volunteer recruitment. All cohorts were dosed on time and in full.”